

Article

Not peer-reviewed version

Structural Barriers, Stochastic Avoidance, and Outbreak Risk in HIV Prevention for People Who Inject Drugs

[AC Demidont](#)*

Posted Date: 13 January 2026

doi: 10.20944/preprints202601.0948.v1

Keywords: HIV prevention; people who inject drugs; PrEP; health disparities; structural barriers; Monte Carlo simulation; harm reduction



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Structural Barriers, Stochastic Avoidance, and Outbreak Risk in HIV Prevention for People Who Inject Drugs

AC Demidont

Nyx Dynamics LLC, Fairfield, Connecticut, USA

* Correspondence: acdemidont@nyxdynamics.org

Abstract

Background: Despite highly efficacious long-acting injectable pre-exposure prophylaxis (LAI-PrEP) achieving >99% efficacy in clinical trials, people who inject drugs (PWID) experience near-zero population-level HIV prevention effectiveness. We hypothesized that nested structural barriers, not pharmacological limitations, explain this disparity. **Methods:** We developed a Monte Carlo simulation modeling an 8-step LAI-PrEP cascade for PWID under current U.S. policy conditions (n=100,000 per scenario). We decomposed barriers into three layers: pathogen biology, HIV testing gaps, and architectural barriers. We compared PWID outcomes to men who have sex with men (MSM) receiving identical pharmacological interventions and modeled stochastic avoidance failure using network density dynamics. **Results:** Under current policy, PWID achieved $P(R_0=0) = 0.003\%$ (95% CI: 0.000-0.006%) compared to 16.3% for MSM—a 5,433-fold disparity. Architectural barriers accounted for 93.2% of cascade failure. Stochastic avoidance modeling predicted 73.8% probability of major outbreak within 5 years (median: 3.0 years). **Conclusions:** Current HIV prevention for PWID relies on probability rather than intervention. Structural barriers create conditions where effective prevention is mathematically impossible regardless of drug efficacy.

Keywords: HIV prevention; people who inject drugs; PrEP; health disparities; structural barriers; Monte Carlo simulation; harm reduction

1. Introduction

The introduction of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) represents a major advance in HIV prevention, with lenacapavir demonstrating >99% efficacy in the PURPOSE-2 trial [1]. Yet people who inject drugs (PWID) remain largely excluded from these benefits. Despite comprising approximately 15.6 million individuals globally and experiencing HIV prevalence rates of 17.8%, [2] PWID oral PrEP uptake remains below 1.5% [3,4].

This disparity cannot be attributed to pharmacological factors. When the same drugs are administered to different populations, identical molecular mechanisms should produce equivalent outcomes. The observation that men who have sex with men (MSM) achieve population-level prevention rates exceeding 16% while PWID remain near zero suggests that non-pharmacological factors dominate outcomes [5,6].

We propose a three-layer barrier framework to explain this disparity. Layer 1 (Pathogen Biology) encompasses the irreversible nature of HIV integration within hours of exposure [7]. Layer 2 (HIV Testing Failures) addresses acute infection detection gaps [8]. Layer 3 (Architectural Barriers) comprises policy-dependent factors including criminalization [9], healthcare stigma,10 MSM-centric infrastructure design [11], and systematic research exclusion [12].

This study applies Monte Carlo simulation to quantify the contribution of each barrier layer to cascade failure, compare PWID and MSM outcomes under identical pharmacological assumptions,

and model the probability of catastrophic outbreak as current “prevention” through stochastic avoidance fails.

2. Methods

2.1. Conceptual Framework

We operationalize HIV prevention success as achieving $R_0=0$, defined as completing the LAI-PrEP cascade and maintaining engagement without incarceration-related disruption [13]. The Prevention Theorem formalizes this constraint: Prevention is only possible while proviral integration remains incomplete [14].

2.2. Cascade Specification

We model an 8-step LAI-PrEP cascade: (1) Awareness, (2) Willingness, (3) Healthcare access, (4) Disclosure, (5) Provider willingness, (6) HIV testing, (7) First injection, and (8) Sustained engagement (Table 1) [3,10,15].

Table 1. Cascade Step Probabilities by Population. PWID probabilities from literature [3,10,15]; MSM probabilities from PrEP implementation studies [6].

Cascade Step	PWID (%)	MSM (%)
1. Awareness	10	90
2. Willingness	30	85
3. Healthcare Access	35	80
4. Disclosure	25	75
5. Provider Willing	35	90
6. HIV Testing	45	85
7. First Injection	45	80
8. Sustained Engagement	25	75
Cascade Completion	0.005	21.1
P($R_0=0$)	0.003	16.3

2.3. Incarceration Disruption

PWID experience annual incarceration rates of approximately 30% [9,16]. We model 5-year survival probability as $(1-0.30)^5 = 16.8\%$ under current policy, compared to 77.4% for MSM [17].

2.4. Monte Carlo Simulation

We simulated 100,000 individuals per policy scenario over 5-year horizons. We calculated observed $P(R_0=0)$ with 95% confidence intervals using normal approximation.

2.5. Stochastic Avoidance Model

We hypothesize that HIV “prevention” among PWID has relied on stochastic avoidance—probability-based non-transmission due to low network density [18,19]. Network density increases with exogenous contextual driver prevalence (growing at 2.5% annually) [20], housing instability (68.5%) [21], modulated by syringe service program coverage [22].

2.6. Signal-to-Noise Ratio Analysis

MSM achieved $SNR=9,180$ (19,800 participants across 9+ trials) versus $SNR=76$ for PWID (2,413 participants in single Bangkok 2013 trial)—a 120-fold disparity.[23,24]

2.7. Use of Artificial Intelligence and Assistive Technologies

The author acknowledges the use of artificial intelligence–assisted tools during manuscript preparation. Computational analyses were conducted using Python with open-source packages including NumPy, Pandas, SciPy, Matplotlib, and Seaborn. Large language models (Anthropic Claude and OpenAI ChatGPT) were used to support literature search and improve readability of the manuscript. JetBrains Junie was used for code correction, and Zotero AI was used for reference management. Manuscript preparation was conducted using the Overleaf LaTeX platform. All AI tools were used as assistive technologies only. The author retains full responsibility for study design, data analysis, interpretation of results, and all conclusions presented.

3. Results

3.1. Cascade Completion and $P(R_0=0)$

Under current policy, PWID achieved $P(R_0=0) = 0.003\%$ (95% CI: 0.000-0.006%) compared to 16.3% for MSM—a 5,433-fold disparity (Figure 1). Step-level analysis revealed that 89.9% of PWID failed at awareness.




Figure 1. LAI-PrEP Cascade Comparison: MSM vs. PWID. Step completion probabilities across the 8-step prevention cascade. MSM (blue) achieve 16.3% $P(R_0=0)$ while PWID (orange) achieve 0.003%—a 5,433-fold disparity.

3.2. Three-Layer Barrier Decomposition

Barrier decomposition (Figure 2) revealed architectural barriers accounted for 93.2% of cascade failure, HIV testing gaps 6.8%, and pathogen biology 0.0%. Within architectural barriers: policy 38.4%, infrastructure 21.9%, stigma 20.5%, algorithmic bias 8.2%, research exclusion 4.1%.




Figure 2. Three-Layer Barrier Decomposition. (A) Primary decomposition: HIV testing 6.8%, architectural 93.2%. (B) Architectural subtypes: Policy 38.4%, Infrastructure 21.9%, Stigma 20.5%, ML bias 8.2%, Research exclusion 4.1%.

3.3. Policy Scenario Analysis

Progressive policy intervention produced substantial improvements (Figure 3; Table 2). Decriminalization increased $P(R_0=0)$ from 0.003% to 0.20%. Full harm reduction achieved 9.55%. Algorithmic debiasing reached 18.57%, exceeding MSM reference.




Figure 3. Policy Scenario Analysis. $P(R_0=0)$ across eight scenarios from Current Policy (0.003%) to Theoretical Maximum (19.74%). Dashed line indicates MSM reference (16.3%).

Table 2. Policy Scenario Results. Monte Carlo simulation (n=100,000 per scenario) showing P(R₀=0).

Scenario	P(R ₀ =0) %	95% CI
Current Policy	0.003	(0.000, 0.006)
Decriminalization Only	0.20	(0.17, 0.23)
Decrim + Stigma Reduction	0.45	(0.41, 0.50)
SSP-Integrated Delivery	5.00	(4.87, 5.14)
Full Harm Reduction	9.55	(9.37, 9.73)
Full HR + PURPOSE-4	11.87	(11.67, 12.07)
Full HR + ML Debiasing	18.57	(18.33, 18.81)
Theoretical Maximum	19.74	(19.49, 19.98)
MSM (Comparison)	16.30	—

3.4. Stochastic Avoidance Failure

The stochastic avoidance model predicted 73.8% probability of major outbreak within 5 years and 92.7% within 10 years (Figure 4). Median time to outbreak was 3.0 years [22,25].




Figure 4. Stochastic Avoidance Failure. (A) Cumulative outbreak probability: 73.8% at 5 years, 92.7% at 10 years. (B) Time-to-outbreak distribution with median 3.0 years (IQR 1-6 years).

3.5. Signal-to-Noise Ratio

The 120-fold SNR disparity (Figure 5) illustrates systematic research exclusion. PWID are validated in exactly one trial.[12,24]




Figure 5. Signal-to-Noise Ratio and LOOCV Framework. (A) MSM SNR=9,180 vs. PWID SNR=76 (120-fold disparity). (B) Training set (19,800) vs. held-out set (2,413).

4. Discussion

Our findings demonstrate that HIV prevention failure among PWID is not a pharmacological problem but an architectural one. The 5,433-fold disparity provides evidence that policy, not biology, determines prevention success.

Three findings warrant attention. First, criminalization accounts for 38.4% of barrier attribution.[9] Second, the 73.8% five-year outbreak probability represents predictable system failure.[18,19] Third, even theoretical maximum achieves only 19.74% effectiveness.

4.1. Limitations

Our barrier parameterization relies on heterogeneous literature sources. The stochastic avoidance model simplifies complex network dynamics.

4.2. Policy Implications

Decriminalization is necessary but insufficient.9 SSP-integrated LAI-PrEP delivery offers efficient mechanisms.[11]

5. Conclusions

HIV prevention for PWID currently relies on stochastic avoidance rather than pharmaceutical intervention. The 5,433-fold disparity represents policy choices, not epidemic inevitability. Predictable outbreaks—with 73.8% probability within 5 years—will reflect failed policy.

Author Contributions: ACD conceived the study, developed the mathematical framework, performed all analyses, and wrote the manuscript.

Funding: This research received no specific funding.

Data Availability Statement: All code and data supporting the findings of this study are publicly available at: https://github.com/Nyx-Dynamics/HIV_Prevention_PWID

Conflicts of Interest: The corresponding author (ACD) reports prior employment with Gilead Sciences, Inc. from January 2020 through November 2024 and prior ownership of company stock, which was fully divested in December 2024. Gilead Sciences, Inc. had no role in the conception, design, analysis, interpretation, or writing of this study, and provided no funding, data, materials, or input into any aspect of the work. The corresponding

author (ACD) is the owner of Nyx Dynamics, LLC, a consulting company providing advisory and fractional leadership services in healthcare, technology, and complex systems. This research was conducted independently, released as open-source work, and was not produced as part of, or in support of, any paid consulting engagement. No other competing interests are declared.

Ethics Approval: Not applicable. This study used published aggregate data and computational modeling without human subjects involvement.

Consent to Participate: Not applicable.

Consent for Publication: Not applicable.

Code Availability: All simulation and analysis code is available at: https://github.com/Nyx-Dynamics/HIV_Prevention_PWID. Key files include: `architectural_barrier_model.py` (prevention cascade simulation), `cascade_sensitivity_analysis.py` (probabilistic sensitivity analysis), `stochastic_avoidance_enhanced.py` (stochastic avoidance and outbreak modeling), and `config/parameters.json` (model parameters with literature sources).

References

1. Marzinke MA, et al. Lenacapavir for HIV prevention in cisgender women. *N Engl J Med*. 2024;391:1277-1288.
2. Degenhardt L, et al. Global prevalence of injecting drug use. *Lancet Glob Health*. 2017;5(12):e1192-e1207.
3. Biello KB, et al. Perspectives on HIV PrEP among people who inject drugs. *Harm Reduct J*. 2018;15(1):55.
4. Kamitani E, et al. HIV pre-exposure prophylaxis best practices: where are PWID? *AIDS Behav*. 2024;28(6):1847-1860.
5. Baugher AR, et al. Are we ending the HIV epidemic among PWID? *AIDS*. 2025;39(12):1813-1819.
6. Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in MSM. *N Engl J Med*. 2010;363(27):2587-2599.
7. Tanner MR, et al. Antiretroviral postexposure prophylaxis—CDC recommendations. *MMWR*. 2025;74(1):1-56.
8. Anderson PL, et al. Emtricitabine-tenofovir concentrations and PrEP efficacy. *Sci Transl Med*. 2012;4(151):151ra125.
9. DeBeck K, et al. HIV and criminalisation of drug use among PWID. *Lancet HIV*. 2017;4(8):e357-e374.
10. Muncan B, et al. Influences of drug use stigma on healthcare engagement. *Harm Reduct J*. 2020;17:53.
11. Strathdee SA, et al. Preventing HIV outbreaks among PWID in the US. *AIDS*. 2020;34(14):1997-2005.
12. Choopanya K, et al. Bangkok Tenofovir Study. *Lancet*. 2013;381(9883):2083-2090.
13. Breban R, et al. Theory versus data: how to calculate R0. *PLoS One*. 2007;2(3):e282.
14. Demidont AC. The HIV Prevention Theorem. *Preprints.org*. 2026.
15. Biello KB, et al. Perspectives on HIV PrEP among PWID. *Drug Alcohol Depend*. 2019;195:108-112.
16. Stone J, et al. Incarceration history and risk of HIV among PWID. *Lancet Infect Dis*. 2018;18(12):1397-1409.
17. Altice FL, et al. The perfect storm: incarceration and HIV transmission. *Lancet*. 2016;388(10050):1228-1248.
18. Des Jarlais DC, et al. HIV infection and intravenous drug use. *Rev Infect Dis*. 1988;10(1):151-158.
19. Alpre C, et al. Opioid use fueling HIV transmission—Massachusetts, 2015-2018. *Am J Public Health*. 2020;110(1):37-44.
20. Glick SN, et al. Increasing methamphetamine injection among PWID. *Drug Alcohol Depend*. 2018;182:86-92.
21. Arum C, et al. Homelessness and HIV acquisition risk among PWID. *Lancet Public Health*. 2021;6(5):e309-e323.
22. Van Handel MM, et al. County-level vulnerability assessment for HIV among PWID. *JAIDS*. 2016;73(3):323-331.
23. Liang S, et al. HIV incidence among PWID—NHBS, 2018. *JAIDS*. 2021;88(2):162-168.
24. Des Jarlais DC, et al. Potential disruptions of HIV prevention among PWID from COVID-19. *Drug Alcohol Depend*. 2022;227:109505.

25. Bonacci RA, et al. Prevention opportunities in HIV outbreak—Kanawha County, WV. J Gen Intern Med. 2023;38(3):828-831.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.